Skip to content

Effect of HIIT (High Intensity Interval Exercise) on Insulin Resistance in Type 2 Diabetics

A Randomized Controlled Trial of the Effect of Body-Weight-Based HIIT (High Intensity Interval Exercise) on Insulin Resistance in Patients with Type 2 Diabetes Mellitus - A Randomized Controlled Trial of the Effect of Body-Weight-Based HIIT on Insulin Resistance in Patients with Type 2 Diabetes Mellitus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000056491
Enrollment
28
Registered
2024-12-18
Start date
2024-02-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

high-intensity interval training Walking No special physical activity (control)

Sponsors

Kobe University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with type 2 diabetes mellitus, not on insulin therapy, and fasting blood glucose level less than 140 mg/dL, and those who do not have an exercise habit (at least twice a week for at least 30 minutes each time).

Exclusion criteria

Exclusion criteria: a person who is unable to perform HIIT due to a musculoskeletal disorder, a person who is restricted from exercising by his/her physician, a person who has a urine ketone body positive and blood glucose level of 250 mg/dL or higher, a person with pre proliferative retinopathy or higher, a person with over manifest nephropathy (eGFR < 30 mL/min/1.73 m2 or urine albumin level > 300 mg/gCr or urinary protein level of 0.5 g/gCr or higher), ischemic heart disease or cardiopulmonary impairment, uncontrolled hypertension (180/110 mmHg or higher), dyslipidemia (LDL cholesterol level of 140 mg/dL or higher, HDL cholesterol level of less than 40 mg/dL, triglyceride level of less than 40 mg/gCr or higher), and other conditions. HDL cholesterol level less than 40 mg/dL, triglyceride level more than 150 mg/dL), and those with a family history of cardiovascular disease or smoking history.

Design outcomes

Primary

MeasureTime frame
Insulin resistance (HOMA-IR)

Secondary

MeasureTime frame
Fasting insulin, fasting blood glucose, heart rate, blood pressure, subjective exercise intensity

Countries

Japan

Contacts

Public ContactKumiko Ono

Kobe University Graduate School of Health Sciences

onoku@tiger.kobe-u.ac.jp078-792-2555

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026